-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FPA-150 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FPA-150 in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FPA-150 in Metastatic Breast Cancer Drug Details: FPA-150 is under development...
-
Product Insights
NewSkin And Soft Tissue Infections – Drugs In Development, 2024
Empower your strategies with our Skin And Soft Tissue Infections – Drugs In Development, 2024 report and make more profitable business decisions. Skin and soft tissue infections are infections involving the layers of the skin and the soft tissues beneath it. Viruses, bacteria, and fungi generally cause skin and soft tissue infections by entering the body where a cut, scrape, bite, or other wound has broken the skin. Symptoms include swelling, warmth, and redness in a distinct area of skin, abscesses,...
-
Product Insights
NewCongenital Heart Disease – Drugs In Development, 2024
Empower your strategies with our Congenital Heart Disease – Drugs In Development, 2024 report and make more profitable business decisions. Congenital heart disease is an impairment of the heart’s structure that is present at birth. It may change the normal flow of blood through the heart. It is the most common type of birth defect, occurring in about 1% of live births in the US. There are different types of congenital heart defects; the most common involve the inside walls of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PLX-51107 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PLX-51107 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drug Details: PLX-51107 was under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OPN-2853 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OPN-2853 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OPN-2853 in Solid Tumor Drug Details: PLX-2853 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FORE-8394 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FORE-8394 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Plixorafenib in Solid Tumor Drug Details: FORE-8394 (PLX-8394) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TMB-365 in Human Immunodeficiency Virus (HIV) Infections (AIDS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TMB-365 in Human Immunodeficiency Virus (HIV) Infections (AIDS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TMB-365 in Human Immunodeficiency Virus (HIV) Infections (AIDS) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nivolumab in Thymic Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Thymic Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nivolumab in Thymic Carcinoma Drug Details: Nivolumab (Opdivo, Opdyta) is a human...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Avoplacel in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Avoplacel in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Avoplacel in Radiation Toxicity (Radiation Sickness, Acute Radiation...